ProteoNic and Oxford Expression Technologies Sign UNic License for Use in flashBAC Protein Expression Platform
Dutch biotech company ProteoNic BV and Oxford Expression Technologies Ltd (OET) have extended their partnership by signing a commercial license agreement.
Leiden, Netherlands/Oxford, United Kingdom, March 7, 2013 / B3C newswire / – Dutch biotech company ProteoNic BV and Oxford Expression Technologies Ltd (OET), a leading provider of baculovirus-based protein expression products and services, have extended their partnership by signing a commercial license agreement. OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services. ProteoNic will provide technical support. Financial terms include upfront and royalty payments.
Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13 and are available for partnering meetings.
Under a previous collaboration, the two companies have successfully combined ProteoNic’s award-winning UNic™ translation enhancing technology with OET’s flashBAC™ system to significantly enhance recombinant protein yields in insect cells. Application of UNic™ not only allows increased overall efficiency and reduction of costs, but also facilitates (pre)clinical development of biopharmaceutical products that otherwise might be discarded due to difficulties in achieving acceptable production levels. This allows biopharmaceutical companies to broaden their pipeline and increase its value while reducing the drug development risk profile. From now on OET’s contract manufacturing services will include UNic™
technology.
Rory Woodhouse, Sales Manager at OET commented: “The combination of the unique UNic™ technology and the flashBAC™ expression system has already proved itself to have a positive effect on eukaryotic protein expression. This new agreement will enable us to build on our partnership and experience with ProteoNic, working together to provide a superior platform for our customers with more challenging to express proteins.”
Victor Schut, Chief Business Officer at ProteoNic added: “We are pleased to have demonstrated the value of partnership in combining two proven technologies. This will allow our customers to benefit from both our expertise through only one service. The successful application of our technology in the flashBAC system adds another recombinant protein production platform to our portfolio enabling us to serve a new market for ProteoNic.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance